The Surviving Sepsis Campaign has created an increased focus on reducing levels of mortality from sepsis. Eli Lilly/BioCritica’s Xigris has been unable to capitalize on what remains a potentially lucrative therapy area with significant unmet needs.
Progress in sepsis drug development has been severely hindered by the complex disease pathogenesis and patient heterogeneity. This module reviews pipeline trends, clinical trial design, and future treatment paradigms for sepsis.
Overview of sepsis definition and a review of the epidemiology literature. This report provides in-depth analysis of patient populations, and 10-year incident case forecast, and key patient segments across the seven major markets.
Edit my basket
© Datamonitor 2013. All rights reserved
Terms & Conditions